Belite Bio Q3 net loss widens on higher R&D expenses

Belite Bio

10/11/2025 13:12

Overview

Belite Bio reports Q3 net loss of $21.7 mln, increased from $8.7 mln last year

Company completed $15 mln direct offering and $125 mln private placement

China's NMPA and UK's MHRA accept Tinlarebant applications based on DRAGON trial

Outlook

Company expects final DRAGON trial data in Q4 2025

Company anticipates interim analysis for PHOENIX trial

Company aims for regulatory milestones with Tinlarebant

Result Drivers

INCREASED R&D EXPENSES - Driven by costs associated with DRAGON and PHOENIX trials, partially offset by Australian R&D tax incentive

FINANCIAL STRENGTHENING - Completion of $15 mln direct offering and $125 mln private placement enhances financial position

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$21.69 mln
Q3 Income From Operations
-$23.02 mln
Q3 Operating Expenses
$23.02 mln
Q3 Pretax Profit
-$21.69 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Belite Bio Inc is $104.00, about 8.8% below its November 7 closing price of $113.19

Press Release: ID:nGNX4z2RCs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)